{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T05:00:06Z","timestamp":1777006806374,"version":"3.51.4"},"reference-count":102,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Metabolically-dysfunction-associated steatotic liver disease (MASLD) represents the most common chronic liver disease in the pediatric population, and its prevalence has doubled over the past decade. The etiology is multifactorial, including genomic risk factors, perinatal and developmental or behavioral factors. Still, many cases of MASLD are associated with being overweight and obesity, particularly in children who have poor dietary habits and sedentary lifestyles that contribute to excessive weight gain. Given the progressive and heterogeneous nature of MASLD, early identification of high-risk patients before the development of severe liver disease is a major clinical priority. Recent studies indicate that disorders of amino acid metabolism are closely linked to both obesity and MASLD, reflecting profound alterations in systemic metabolic homeostasis. The reported data sustain significant changes in circulating amino acid profiles, particularly elevated levels of branched-chain amino acids (BCAAs) and aromatic amino acids. These alterations are thought to reflect fundamental metabolic disturbances, including insulin resistance, compromised mitochondrial activity, and altered hepatic lipid metabolism. Consequently, alterations in amino acid metabolism have been proposed as potential biomarkers for disease progression and metabolic dysfunction in MASLD. This review aims to evaluate the correlation between the amino acid profile and histological changes in pediatric MASLD, including steatosis, steatohepatitis, and fibrosis.<\/jats:p>","DOI":"10.3390\/ijms27083596","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T14:24:51Z","timestamp":1776435891000},"page":"3596","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Amino Acids\u2014Potential Biomarkers of Histological Features for MASLD in Pediatric Obesity"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-1486-6126","authenticated-orcid":false,"given":"Diana","family":"Zamosteanu","sequence":"first","affiliation":[{"name":"Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0949-7538","authenticated-orcid":false,"given":"Nina","family":"Filip","sequence":"additional","affiliation":[{"name":"Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3994-6579","authenticated-orcid":false,"given":"Ludmila","family":"Lozneanu","sequence":"additional","affiliation":[{"name":"Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona Eliza","family":"Giusca","sequence":"additional","affiliation":[{"name":"Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7050-8430","authenticated-orcid":false,"given":"Oana Viola","family":"Badulescu","sequence":"additional","affiliation":[{"name":"Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5308-7192","authenticated-orcid":false,"given":"Mihaela","family":"Pertea","sequence":"additional","affiliation":[{"name":"Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandru","family":"Filip","sequence":"additional","affiliation":[{"name":"Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Ungureanu","sequence":"additional","affiliation":[{"name":"Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenia","family":"Morosan","sequence":"additional","affiliation":[{"name":"Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7859-840X","authenticated-orcid":false,"given":"Elena","family":"Cojocaru","sequence":"additional","affiliation":[{"name":"Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Di Cesare, M., Sori\u0107, M., Bovet, P., Miranda, J.J., Bhutta, Z., Stevens, G.A., Laxmaiah, A., Kengne, A.-P., and Bentham, J. (2019). The epidemiological burden of obesity in childhood: A worldwide epidemic requiring urgent action. BMC Med., 17.","DOI":"10.1186\/s12916-019-1449-8"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Umano, G.R., Bellone, S., Buganza, R., Calcaterra, V., Corica, D., De Sanctis, L., Di Sessa, A., Faienza, M.F., Improda, N., and Licenziati, M.R. (2025). Early roots of childhood obesity: Risk factors, mechanisms, and prevention strategies. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26157388"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S2213-8587(22)00047-X","article-title":"Obesity in children and adolescents: Epidemiology, causes, assessment, and management","volume":"10","author":"Jebeile","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Accacha, S., Barillas-Cerritos, J., Srivastava, A., Ross, F., Drewes, W., Gulkarov, S., De Leon, J., and Reiss, A.B. (2025). From childhood obesity to metabolic dysfunction-associated steatotic liver disease (MASLD) and hyperlipidemia through oxidative stress during childhood. Metabolites, 15.","DOI":"10.3390\/metabo15050287"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Montagnana, M., Danese, E., Bonafini, S., and Fava, C. (2026). Childhood obesity: A multisystem challenge linking hypertension, NAFLD, and sleep apnea. Med. Sci., 14.","DOI":"10.3390\/medsci14010070"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Menendez, A., Wanczyk, H., Walker, J., Zhou, B., Santos, M., and Finck, C. (2022). Obesity and adipose tissue dysfunction: From pediatrics to adults. Genes, 13.","DOI":"10.3390\/genes13101866"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Vajravelu, M.E., Tas, E., and Arslanian, S. (2023). Pediatric obesity: Complications and current day management. Life, 13.","DOI":"10.3390\/life13071591"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"103043","DOI":"10.1016\/j.arcmed.2024.103043","article-title":"Global prevalence of nonalcoholic fatty liver disease: An updated review meta-analysis comprising a population of 78 million from 38 countries","volume":"55","author":"Letafatkar","year":"2024","journal-title":"Arch. Med. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"100485","DOI":"10.1016\/j.jlr.2023.100485","article-title":"From NAFLD to MASLD: Updated naming and diagnosis criteria for fatty liver disease","volume":"65","author":"Rinella","year":"2024","journal-title":"J. Lipid Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1016\/j.jhep.2024.01.004","article-title":"Comparative evaluation of pediatric fatty liver disease criteria: MASLD, ESPGHAN, NASPGHAN, and NAFLD\u2014Identifying the optimal pediatric label","volume":"80","author":"Wang","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.jhep.2024.01.014","article-title":"Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease","volume":"80","author":"Younossi","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_13","first-page":"101717","article-title":"Pediatric MASLD in China: Epidemiology, screening, diagnosis, and management","volume":"64","author":"Li","year":"2025","journal-title":"Lancet Reg. Health West. Pac."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/MPG.0000000000001482","article-title":"NASPGHAN clinical practice guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in children","volume":"64","author":"Vos","year":"2017","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Hou, Y., Hu, S., Li, X., He, W., and Wu, G. (2020). Amino acid metabolism in the liver: Nutritional and physiological significance. Amino Acids in Nutrition and Health: Amino Acids in Systems Function and Health, Springer.","DOI":"10.1007\/978-3-030-45328-2_2"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Cojocaru, E., Magdalena Leon-Constantin, M., Ungureanu, C., Trandafirescu, M.F., Ma\u0219taleru, A., Mihaela Trandafir, L., Dumitru Petrariu, F., Viola B\u0103dulescu, O., and Filip, N. (2021). Hypolipemiant Actions and Possible Cardioprotective Effects of Valine and Leucine: An Experimental Study. Medicina, 57.","DOI":"10.3390\/medicina57030239"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3892\/etm.2020.9154","article-title":"Abnormal metabolic processes involved in the pathogenesis of non-alcoholic fatty liver disease","volume":"20","author":"Shao","year":"2020","journal-title":"Exp. Ther. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1152\/physrev.00035.2018","article-title":"Metabolomics for investigating physiological and pathophysiological processes","volume":"99","author":"Wishart","year":"2019","journal-title":"Physiol. Rev."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Ma, J., Ma, Y., Wan, X., Li, J., Zhang, Y., Liu, J., and Gao, Y. (2025). Metabolic and genetic mechanisms of metabolic dysfunction-associated steatotic liver disease: An integrative perspective from molecular pathways to clinical challenges. Front. Endocrinol., 16.","DOI":"10.3389\/fendo.2025.1639064"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Balderas-Pe\u00f1a, L.M.A., Sat-Mu\u00f1oz, D., Mireles-Ram\u00edrez, M.A., Mart\u00ednez-Herrera, B.E., Nava-Zavala, A.H., Cervantes-Gonz\u00e1lez, L.M., Mu\u00f1oz-Garc\u00eda, M.-G., Rubio-Jurado, B., P\u00e1ramo, M.S., and S\u00e1nchez, E.G. (2023). Influence of chronic low-grade inflammation (obesity) on the systemic inflammatory response. Multisystem Inflammatory Syndrome\u2014Natural History, Intech Open.","DOI":"10.5772\/intechopen.1002764"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Szukiewicz, D. (2023). Molecular mechanisms for the vicious cycle between insulin resistance and the inflammatory response in obesity. Int. J. Mol. Sci., 24.","DOI":"10.20944\/preprints202305.1026.v1"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Podeanu, M.-A., Ionele, C.M., Sandu, R.E., Rogoveanu, I., Stepan, M.D., Niculescu, C.E., Cazacu, S.-M., and Vintilescu, \u0218.B. (2026). Obesity, metabolic syndrome and MASLD in children: Inflammation as the missing link\u2014A short narrative review. Life, 16.","DOI":"10.3390\/life16020310"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"S157","DOI":"10.2337\/dc09-S302","article-title":"Skeletal muscle insulin resistance is the primary defect in type 2 diabetes","volume":"32","author":"DeFronzo","year":"2009","journal-title":"Diabetes Care"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Zhao, X., An, X., Yang, C., Sun, W., Ji, H., and Lian, F. (2023). The crucial role and mechanism of insulin resistance in metabolic disease. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1149239"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1152\/physrev.00063.2017","article-title":"Mechanisms of insulin action and insulin resistance","volume":"98","author":"Petersen","year":"2018","journal-title":"Physiol. Rev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1172\/JCI25735","article-title":"Irs1 and Irs2 signaling is essential for hepatic glucose homeostasis and systemic growth","volume":"116","author":"Dong","year":"2006","journal-title":"J. Clin. Investig."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.cmet.2024.04.006","article-title":"Hepatic selective insulin resistance at the intersection of insulin signaling and metabolic dysfunction-associated steatotic liver disease","volume":"36","author":"Bo","year":"2024","journal-title":"Cell Metab."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1038\/s42255-021-00493-6","article-title":"Lipolysis: Cellular mechanisms for lipid mobilization from fat stores","volume":"3","author":"Grabner","year":"2021","journal-title":"Nat. Metab."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Dop, D., P\u0103dureanu, V., P\u0103dureanu, R., Niculescu, C.E., Niculescu, \u0218.A., and Marcu, I.R. (2025). Diagnosis and management of pediatric non-alcoholic fatty liver disease: An overview. Metabolites, 15.","DOI":"10.3390\/metabo15120792"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Saad, R.A., and Qutob, H.M. (2023). Inter-relationships of pediatric obesity and mitochondrial dysfunction. Med. Sci. Forum, 21.","DOI":"10.3390\/ECB2023-14336"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41575-018-0082-x","article-title":"The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"16","author":"Kazankov","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"18070","DOI":"10.3748\/wjg.v20.i48.18070","article-title":"Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease","volume":"20","author":"Duvnjak","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"102114","DOI":"10.1016\/j.gde.2023.102114","article-title":"Adipose tissue lipid metabolism: Lipolysis","volume":"83","author":"Cho","year":"2023","journal-title":"Curr. Opin. Genet. Dev."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Jalloul, W., Grierosu, I.C., Jalloul, D., Stefanescu, C., and Ghizdovat, V. (2025). Functional complexity of thermogenic adipose tissue: From thermogenesis to metabolic and fibroinflammatory crosstalk. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26189045"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Dimitriadis, G.D., Maratou, E., Kountouri, A., Board, M., and Lambadiari, V. (2021). Regulation of postabsorptive and postprandial glucose metabolism by insulin-dependent and insulin-independent mechanisms: An integrative approach. Nutrients, 13.","DOI":"10.3390\/nu13010159"},{"key":"ref_36","first-page":"815","article-title":"Mechanism of metabolic dysfunction-associated steatotic liver disease: Important role of lipid metabolism","volume":"12","author":"Feng","year":"2024","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e0375","DOI":"10.1097\/HC9.0000000000000375","article-title":"Validation of a screening panel for pediatric metabolic dysfunction-associated steatotic liver disease using metabolomics","volume":"8","author":"Huneault","year":"2024","journal-title":"Hepatol. Commun."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e70080","DOI":"10.1111\/ijpo.70080","article-title":"Starting age for screening metabolic dysfunction-associated steatotic liver disease in children using controlled attenuation parameter on transient elastography","volume":"21","author":"Lee","year":"2026","journal-title":"Pediatr. Obes."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Sannidhi, D., Abeles, R., Andrew, W., Bonnet, J.P., Vitale, K., Niranjan, V., Gulati, M., Pauly, K., Moran, R., and Alexander, L. (2025). Lifestyle medicine for obesity in the era of highly effective anti-obesity treatment. Nutrients, 17.","DOI":"10.3390\/nu17142382"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Lahtinen, L., Hiltunen, P., Vuorela, N., Huhtala, H., Kurppa, K., and Aitokari, L. (2025). Screening and diagnosis of metabolic dysfunction-associated steatotic liver disease in children within public healthcare. Pediatr. Res., Online ahead of print.","DOI":"10.1038\/s41390-025-04540-w"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1111\/apt.17866","article-title":"Diagnosis and non-invasive assessment of MASLD in type 2 diabetes and obesity","volume":"59","author":"Chan","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/jpn3.12068","article-title":"Noninvasive scores are poorly predictive of histological fibrosis in paediatric fatty liver disease","volume":"78","author":"Kalveram","year":"2024","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Bozic, D., Podrug, K., Mikolasevic, I., and Grgurevic, I. (2022). Ultrasound methods for the assessment of liver steatosis: A critical appraisal. Diagnostics, 12.","DOI":"10.3390\/diagnostics12102287"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"111211","DOI":"10.4254\/wjh.v18.i1.111211","article-title":"Fighting the epidemic of pediatric metabolic dysfunction-associated steatotic liver disease: Role of non-invasive diagnostics and early pharmacological intervention","volume":"18","author":"Ng","year":"2026","journal-title":"World J. Hepatol."},{"key":"ref_45","unstructured":"Indre, M.G. (2025). Metabolic Dysfunction-Associated Steatotic Liver Disease: Non-Invasive Assessment of Disease Progression. [Doctoral Dissertation, Alma Mater Studiorum Universit\u00e0 di Bologna]."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Yang, L., Zhu, Y., Zhou, L., Yin, H., Lin, Y., and Wu, G. (2022). Transient elastography in the diagnosis of pediatric non-alcoholic fatty liver disease and its subtypes. Front. Pediatr., 10.","DOI":"10.3389\/fped.2022.808997"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/cld.994","article-title":"Imaging modalities in pediatric NAFLD","volume":"17","author":"Serai","year":"2021","journal-title":"Clin. Liver Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1055\/s-0042-1742577","article-title":"Sedation and general anesthesia in diagnostic pediatric imaging","volume":"1","author":"Choudhary","year":"2022","journal-title":"Indographics"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/s41390-021-01754-6","article-title":"Predictors of non-alcoholic fatty liver disease in children","volume":"92","author":"Li","year":"2022","journal-title":"Pediatr. Res."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Francque, S.M., and Driessen, A. (2024). Histopathology of MASLD: Insights into liver tissue changes. Metabolic Dysfunction-Associated Steatotic Liver Disease: Prevalence, Research Insights and the Future Directions, Springer Nature.","DOI":"10.1007\/978-981-97-9519-2_6"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Choi, E., Ramirez Tovar, A., He, Z., Soler Rodriguez, D.M., Vos, M.B., Arora, S., and Fadoju, D. (2024). Glucagon-like peptide-1 receptor agonists\u2014A potential new medication for pediatric metabolic-dysfunction-associated steatotic liver disease (MASLD). Children, 11.","DOI":"10.3390\/children11030275"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1056\/NEJMoa2208601","article-title":"Once-weekly semaglutide in adolescents with obesity","volume":"387","author":"Weghuber","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Al-Busafi, S.A., and Eslam, M. (2025). Liver transplantation in the era of metabolic dysfunction\u2013associated fatty liver disease: Challenges, ethical dilemmas, and future directions. Transplantology, 6.","DOI":"10.3390\/transplantology6040035"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Pecani, M., Andreozzi, P., Cangemi, R., Corica, B., Miglionico, M., Romiti, G.F., Stefanini, L., Raparelli, V., and Basili, S. (2025). Metabolic syndrome and liver disease: Re-appraisal of screening, diagnosis, and treatment through the paradigm shift from NAFLD to MASLD. J. Clin. Med., 14.","DOI":"10.3390\/jcm14082750"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Portincasa, P., Khalil, M., Mahdi, L., Perniola, V., Idone, V., Graziani, A., Baffy, G., and Di Ciaula, A. (2024). Metabolic dysfunction\u2013associated steatotic liver disease: From pathogenesis to current therapeutic options. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25115640"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1053\/j.gastro.2016.03.009","article-title":"Comparison of the phenotype and approach to pediatric vs adult patients with nonalcoholic fatty liver disease","volume":"150","author":"Nobili","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/hep.20842","article-title":"Histopathology of pediatric nonalcoholic fatty liver disease","volume":"42","author":"Schwimmer","year":"2005","journal-title":"Hepatology"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.cld.2015.10.011","article-title":"Histology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in adults and children","volume":"20","author":"Kleiner","year":"2016","journal-title":"Clin. Liver Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e70137","DOI":"10.1002\/jgh3.70137","article-title":"Consensus statement on metabolic dysfunction-associated steatotic liver disease in children and adolescents from the joint TASL-TSPGHAN expert committee","volume":"9","author":"Lin","year":"2025","journal-title":"JGH Open"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Sergi, C.M. (2024). NAFLD (MASLD)\/NASH (MASH): Does it bother to label at all? A comprehensive narrative review. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25158462"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Lefere, S., Koot, B.G., Mann, J.P., Bufler, P., De Bruyne, R., and Hudert, C.A. (2026). Update in clinical science: MASLD in children and adolescents. J. Hepatol., Online ahead of print.","DOI":"10.1016\/j.jhep.2026.02.016"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/hep.23133","article-title":"Nonalcoholic steatohepatitis in children: A multicenter clinicopathological study","volume":"50","author":"Yerian","year":"2009","journal-title":"Hepatology"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Giorgio, V., Prono, F., Graziano, F., and Nobili, V. (2013). Pediatric non alcoholic fatty liver disease: Old and new concepts on development, progression, metabolic insight and potential treatment targets. BMC Pediatr., 13.","DOI":"10.1186\/1471-2431-13-40"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"15539","DOI":"10.3748\/wjg.v20.i42.15539","article-title":"Histopathology of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"20","author":"Takahashi","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1111\/j.1572-0241.1999.01377.x","article-title":"Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions","volume":"94","author":"Brunt","year":"1999","journal-title":"Am. J. Gastroenterol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/hep.25889","article-title":"Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients","volume":"56","author":"Bedossa","year":"2012","journal-title":"Hepatology"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Cheng, S., Wiklund, P., Autio, R., Borra, R., Ojanen, X., Xu, L., T\u00f6rm\u00e4kangas, T., and Alen, M. (2015). Adipose tissue dysfunction and altered systemic amino acid metabolism are associated with non-alcoholic fatty liver disease. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0138889"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Zamosteanu, D., Filip, N., Trandafir, L.M., \u0162arc\u0103, E., Pertea, M., Bordeianu, G., Bernic, J., Heredea, A.M., and Cojocaru, E. (2025). Current Data on the Role of Amino Acids in the Management of Obesity in Children and Adolescents. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26157129"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s13105-025-01086-7","article-title":"Alterations in hepatic amino acid metabolism related to MASLD in individuals with obesity","volume":"81","author":"Yuste","year":"2025","journal-title":"J. Physiol. Biochem."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Chae, W., Lee, K.J., Huh, K.Y., Moon, J.S., Ko, J.S., and Cho, J.-Y. (2022). Association of metabolic signatures with nonalcoholic fatty liver disease in pediatric population. Metabolites, 12.","DOI":"10.3390\/metabo12090881"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Polidori, N., Grasso, E.A., Chiarelli, F., and Giannini, C. (2022). Amino acid-related metabolic signature in obese children and adolescents. Nutrients, 14.","DOI":"10.3390\/nu14071454"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1002\/hep4.1417","article-title":"Development of a plasma screening panel for pediatric nonalcoholic fatty liver disease using metabolomics","volume":"3","author":"Khusial","year":"2019","journal-title":"Hepatol. Commun."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/s12276-023-01028-7","article-title":"Immune regulation through tryptophan metabolism","volume":"55","author":"Seo","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1038\/s41467-026-69735-z","article-title":"Clinically distinct metabotypes of pediatric MASLD identified through unsupervised clustering of NASH CRN data","volume":"17","author":"Huneault","year":"2026","journal-title":"Nat. Commun."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"7544","DOI":"10.1111\/dom.70162","article-title":"Tryptophan derivatives as non-invasive diagnostic indicators for obesity-related MASLD in children and adolescents","volume":"27","author":"Zhan","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/j.1440-1746.2005.03901.x","article-title":"Hydroxyproline content of needle biopsies as an objective measure of liver fibrosis: Emphasis on sampling variability","volume":"20","author":"Lee","year":"2005","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"17935","DOI":"10.1038\/s41598-022-22902-w","article-title":"Automated whole slide image analysis for a translational quantification of liver fibrosis","volume":"12","author":"Serdjebi","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e186422","DOI":"10.1172\/JCI186422","article-title":"MASLD in children: Integrating epidemiological trends with mechanistic and translational advances","volume":"135","author":"Schwimmer","year":"2025","journal-title":"J. Clin. Investig."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Kordy, K., Li, F., Lee, D.J., Kinchen, J.M., Jew, M.H., La Rocque, M.E., Zabih, S., Saavedra, M., Woodward, C., and Cunningham, N.J. (2021). Metabolomic predictors of non-alcoholic steatohepatitis and advanced fibrosis in children. Front. Microbiol., 12.","DOI":"10.3389\/fmicb.2021.713234"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Goffredo, M., Santoro, N., Tric\u00f2, D., Giannini, C., D\u2019Adamo, E., Zhao, H., Peng, G., Yu, X., Lam, T.T., and Pierpont, B. (2017). A branched-chain amino acid-related metabolic signature characterizes obese adolescents with non-alcoholic fatty liver disease. Nutrients, 9.","DOI":"10.3390\/nu9070642"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jpeds.2016.01.026","article-title":"Amino acid metabolism is altered in adolescents with nonalcoholic fatty liver disease\u2014An untargeted, high resolution metabolomics study","volume":"172","author":"Jin","year":"2016","journal-title":"J. Pediatr."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e12739","DOI":"10.1111\/ijpo.12739","article-title":"A branched-chain amino acid-based metabolic score can predict liver fat in children and adolescents with severe obesity","volume":"16","author":"Lischka","year":"2021","journal-title":"Pediatr. Obes."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Delgado, T.C., de las Heras, J., and Mart\u00ednez-Chantar, M.L. (2022). Understanding gut\u2013liver axis nitrogen metabolism in fatty liver disease. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.1058101"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1038\/s41419-022-05409-0","article-title":"Targeting glutamine metabolism in hepatic stellate cells alleviates liver fibrosis","volume":"13","author":"Yin","year":"2022","journal-title":"Cell Death Dis."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Jamshidi, N., Feizi, A., Sirlin, C.B., Lavine, J.E., and Kuo, M.D. (2023). Multi-modality, multi-dimensional characterization of pediatric non-alcoholic fatty liver disease. Metabolites, 13.","DOI":"10.3390\/metabo13080929"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1053\/j.gastro.2008.03.003","article-title":"Mechanisms of hepatic fibrogenesis","volume":"134","author":"Friedman","year":"2008","journal-title":"Gastroenterology"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"goaf056","DOI":"10.1093\/gastro\/goaf056","article-title":"Metabolic dysfunction-associated steatotic liver disease is associated with the risk of severe liver fibrosis in pediatric population","volume":"13","author":"Li","year":"2025","journal-title":"Gastroenterol. Rep."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Van den Berg, E.H., Flores-Guerrero, J.L., Gruppen, E.G., de Borst, M.H., Wolak-Dinsmore, J., Connelly, M.A., Bakker, S.J.L., and Dullaart, R.P.F. (2019). Non-alcoholic fatty liver disease and risk of incident type 2 diabetes: Role of circulating branched-chain amino acids. Nutrients, 11.","DOI":"10.3390\/nu11030705"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Hasegawa, T., Iino, C., Endo, T., Mikami, K., Kimura, M., Sawada, N., Nakaji, S., and Fukuda, S. (2020). Changed amino acids in NAFLD and liver fibrosis: A large cross-sectional study without influence of insulin resistance. Nutrients, 12.","DOI":"10.20944\/preprints202005.0127.v1"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"14485","DOI":"10.1038\/s41598-017-14974-w","article-title":"Plasma amino acid profile associated with fatty liver disease and co-occurrence of metabolic risk factors","volume":"7","author":"Yamakado","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1002\/hep.28482","article-title":"Hepatic mitochondrial dysfunction in nonalcoholic steatohepatitis: Read-out or reason?","volume":"63","author":"Trebicka","year":"2016","journal-title":"Hepatology"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jhep.2022.09.020","article-title":"Mitochondrial alterations in fatty liver diseases","volume":"78","author":"Fromenty","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Garibay-Nieto, N., Pedraza-Escudero, K., Oma\u00f1a-Guzm\u00e1n, I., Garc\u00e9s-Hern\u00e1ndez, M.J., Villanueva-Ortega, E., Flores-Torres, M., P\u00e9rez-Hern\u00e1ndez, J.L., Le\u00f3n-Hern\u00e1ndez, M., Laresgoiti-Servitje, E., and Palacios-Gonz\u00e1lez, B. (2023). Metabolomic phenotype of hepatic steatosis and fibrosis in Mexican children living with obesity. Medicina, 59.","DOI":"10.3390\/medicina59101785"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1007\/s00535-013-0766-5","article-title":"Serum metabolomic profile and potential biomarkers for severity of fibrosis in nonalcoholic fatty liver disease","volume":"48","author":"Tokushige","year":"2013","journal-title":"J. Gastroenterol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11306-020-01756-1","article-title":"Untargeted metabolomics as a diagnostic tool in NAFLD: Discrimination of steatosis, steatohepatitis and cirrhosis","volume":"17","author":"Masarone","year":"2021","journal-title":"Metabolomics"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jare.2024.02.007","article-title":"A narrative review about cognitive impairment in metabolic dysfunction\u2013associated steatotic liver disease (MASLD): Another matter to face through a holistic approach","volume":"68","author":"Meroni","year":"2025","journal-title":"J. Adv. Res."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Sandireddy, R., Sakthivel, S., Gupta, P., Behari, J., Tripathi, M., and Singh, B.K. (2024). Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases. Front. Cell Dev. Biol., 12.","DOI":"10.3389\/fcell.2024.1433857"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Mej\u00eda-Guzm\u00e1n, J.E., Belmont-Hern\u00e1ndez, R.A., Ch\u00e1vez-Tapia, N.C., Uribe, M., and Nu\u00f1o-L\u00e1mbarri, N. (2025). Metabolic-dysfunction-associated steatotic liver disease: Molecular mechanisms, clinical implications, and emerging therapeutic strategies. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26072959"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Kinny-K\u00f6ster, B., Bartels, M., Becker, S., Scholz, M., Thiery, J., Ceglarek, U., and Kaiser, T. (2016). Plasma amino acid concentrations predict mortality in patients with end-stage liver disease. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0159205"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Babu, A.F. (2025). Metabolic signatures in lean MASLD: Current insights and future directions. Metabolites, 15.","DOI":"10.3390\/metabo15090583"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Beyo\u011flu, D., Popov, Y.V., and Idle, J.R. (2024). Metabolomic hallmarks of obesity and metabolic dysfunction-associated steatotic liver disease. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252312809"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/8\/3596\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T04:26:16Z","timestamp":1777004776000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/8\/3596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":102,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["ijms27083596"],"URL":"https:\/\/doi.org\/10.3390\/ijms27083596","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]}}}